Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain-Reference-Cited by-同舟云学术

Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain

Published:2023-08-21 Issue:1 Volume:26 Page:1145-1154
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Muñoz Andrés J.¹^ORCID,Ortega Laura¹^ORCID,Gutiérrez Ana¹^ORCID,Gallardo Enrique²^ORCID,Rubio-Rodríguez Darío³,Rubio-Terrés Carlos³,Morón Blanca¹^ORCID,García-Alfonso Pilar¹^ORCID,Soria José Manuel⁴^ORCID

Affiliation:

1. Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain

2. Medical Oncology Service, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona. Sabadell, Spain

3. Health Value, Madrid, Spain

4. Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, España

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2248839

Reference41 articles.

1. Venous thromboembolism in cancer patients: a population-based cohort study

2. A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study

3. Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis

4. Cancer-associated thrombosis: updates and controversies

5. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study